Ocular Therapeutix Inc (OCUL)

Ocular Therapeutix, Inc. experienced several stock events in the past six months. In February 2026, shares plummeted despite positive topline results for AXPAXLI due to unmet investor expectations. In March 2026, the stock jumped following a presentation at the TD Cowen conference. The company reported Q4 2025 earnings in February 2026 with an EPS of -0.290 USD. In May 2026, Q1 2026 financial results revealed a wider net loss, with a slight increase in total net revenue driven by DEXTENZA sales. Analyst sentiment is mixed, with some reiterating "Buy" ratings and others lowering EPS estimates.

Information regarding specific demand seasonality for Ocular Therapeutix, Inc.'s products and services is not readily available. However, tools exist to analyze monthly seasonality and historical price patterns for the stock over several years.

Ocular Therapeutix, Inc. is a biotechnology company focused on developing and commercializing therapies for eye diseases, utilizing its hydrogel platform technology to deliver therapeutic agents. Its key products and pipeline candidates include DEXTENZA for post-surgical ocular inflammation and allergic conjunctivitis, ReSure Sealant for preventing post-surgical leakage during cataract surgery, AXPAXLI (OTX-TKI) in Phase 3 trials for wet AMD and diabetic retinal disease, OTX-TIC which has completed Phase 2 trials for glaucoma or ocular hypertension, and OTX-IVT.

Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts, United States, where its corporate headquarters and manufacturing facilities are located. The company holds worldwide exclusive commercial rights to its core technology and has a license agreement with AffaMed Therapeutics Limited for DEXTENZA and PAXTRAVA in specific regions of Asia.

Ocular Therapeutix's brand reputation has been influenced by clinical trial results and market perception. Despite positive Phase 3 data for AXPAXLI, the stock plunged due to unmet investor expectations regarding dosing intervals. Recent analyst commentary shows generally positive sentiment, with several firms maintaining "Buy" ratings, suggesting long-term value and pipeline progress are still viewed favorably.

Ocular Therapeutix, Inc. is primarily owned by institutional shareholders, who hold 88.00% of the stock, insiders own 17.12%, and retail investors hold 0.00%. Major institutional owners include Fmr LLC, Blackrock Inc., and Vanguard Group Inc. Opaleye Management Inc. is the largest individual shareholder, owning 10.21 million shares, representing 4.69% of the company.